Intranasal administration of Exendin-4 antagonizes Aβ31–35-induced disruption of circadian rhythm and impairment of learning and memory

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Aging Clinical and Experimental Research

• Publication date

  2016-02-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s40520-016-0548-zPMID 26920423
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Aβ-induced degradation of BMAL1 and CBP leads to circadian rhythm disruption in Alzheimer’s disease

  2015cited by this paper
• Rapid Adjustment of Circadian Clocks to Simulated Travel to Time Zones across the Globe

  2015cited by this paper
• The GLP-1 Receptor Agonist Liraglutide Improves Memory Function and Increases Hippocampal CA1 Neuronal Numbers in a Senescence-Accelerated Mouse Model of Alzheimer’s Disease

  2015cited by this paper
• Sleep and Alzheimer's disease.

  2015cited by this paper
• Intranasal delivery: circumventing the iron curtain to treat neurological disorders

  2015cited by this paper
• Targeting glioblastoma via intranasal administration of Ff bacteriophages

  2015cited by this paper
• Intranasal delivery of progesterone after transient ischemic stroke decreases mortality and provides neuroprotection.

  2015cited by this paper
• Injection of β-amyloid into the hippocampus induces metabolic disturbances and involuntary weight loss which may be early indicators of Alzheimer’s disease

  2014cited by this paper
• Associations between circadian activity rhythms and functional brain abnormalities among euthymic bipolar patients: a preliminary study.

  2014cited by this paper
• GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance

  2014cited by this paper
• Repurposing Diabetes Drugs for Brain Insulin Resistance in Alzheimer Disease

  2014cited by this paper
• Effects of amyloid β-peptide fragment 31-35 on the BK channel-mediated K⁺ current and intracellular free Ca²⁺ concentration of hippocampal CA1 neurons.

  2014cited by this paper
• Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases.

  2014cited by this paper
• Val8‐GLP‐1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid β peptide in rats

  2013cited by this paper
• Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a.

  2013cited by this paper
• Potential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection

  2012cited by this paper
• An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Aβ oligomers.

  2012cited by this paper
• Exendin-4 Protected against Cognitive Dysfunction in Hyperglycemic Mice Receiving an Intrahippocampal Lipopolysaccharide Injection

  2012cited by this paper
• Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia

  2011cited by this paper
• GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease

  2010cited by this paper
• Brain targeting studies on buspirone hydrochloride after intranasal administration of mucoadhesive formulation in rats

  2009cited by this paper
• Brain Glucagon-Like Peptide-1 Regulates Arterial Blood Flow, Heart Rate, and Insulin Sensitivity

  2008cited by this paper
• Neurodegeneration and Alzheimer’s disease: the lesson from tauopathies

  2007cited by this paper
• Intrahippocampal administration of Aβ1-40 impairs spatial learning and memory in hyperglycemic mice

  2007cited by this paper
• Alzheimer's disease

  2006cited by this paper
• Entry of exendin-4 into brain is rapid but may be limited at high doses

  2003cited by this paper
• Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

  2003cited by this paper
• Glucagon‐like peptide‐1 decreases endogenous amyloid‐β peptide (Aβ) levels and protects hippocampal neurons from death induced by Aβ and iron

  2003cited by this paper
• Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.

  2003cited by this paper
• Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4

  2002cited by this paper
• Sleep in normal aging and dementia.

  1993cited by this paper
• Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas.

  1992cited by this paper

• Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer’s Disease

  2025cites this paper
• Role of Glucagon-Like Peptide-1 on Amyloid, Tau, and α-Synuclein: Target Engagement and Rationale for the Development in Neurodegenerative Disorders.

  2025influential citation
• THERAPEUTIC POTENTIAL OF GLP-1 RECEPTOR AGONISTS IN ALZHEIMER’S DISEASE: INSIGHTS FROM PRECLINICAL AND CLINICAL EVIDENCE

  2025cites this paper
• Effect of antidiabetic drugs in Alzheimer´s disease: a systematic review of preclinical and clinical studies

  2025cites this paper
• Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension

  2024cites this paper
• Neuroprotective effect of Hibiscus sabdariffa extract against high glucose-induced toxicity in Neuro-2a cells and Caenorhabditis elegans

  2023cites this paper
• Exendin‐4: A potential therapeutic strategy for Alzheimer's disease and Parkinson's disease

  2023cites this paper
• Melatonin protects HT-22 cells against palmitic acid-induced glucolipid metabolic dysfunction and cell injuries: Involved in the regulation of synaptic plasticity and circadian rhythms.

  2023cites this paper
• Circadian disruption and sleep disorders in neurodegeneration

  2023cites this paper
• Crosstalk between Alzheimer’s disease and diabetes: a focus on anti-diabetic drugs

  2023cites this paper
• Role of Bmal1 in Type 2 Diabetes Mellitus-Related Glycolipid Metabolic Disorder and Neuropsychiatric Injury: Involved in the Regulation of Synaptic Plasticity and Circadian Rhythms

  2023cites this paper
• Glucagon-like peptide 1 (GLP-1) receptor agonists in experimental Alzheimer’s disease models: a systematic review and meta-analysis of preclinical studies

  2023cites this paper
• The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease

  2022cites this paper
• Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer's Disease.

  2022cites this paper
• The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review

  2022cites this paper
• Incretin-based drugs as potential therapy for neurodegenerative diseases: Current status and perspectives.

  2022cites this paper
• RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus

  2022cites this paper
• Intranasal Peptide Therapeutics: A Promising Avenue for Overcoming the Challenges of Traditional CNS Drug Development

  2022cites this paper
• Association between exenatide use and incidence of Alzheimer's disease

  2021cites this paper
• Type 2 Diabetes Mellitus Drugs for Alzheimer's Disease: Current Evidence and Therapeutic Opportunities.

  2020cites this paper
• Non-invasive 40-Hz Light Flicker Ameliorates Alzheimer’s-Associated Rhythm Disorder via Regulating Central Circadian Clock in Mice

  2020cites this paper
• D‐Ser2‐oxyntomodulin ameliorated Aβ31‐35‐induced circadian rhythm disorder in mice

  2019cites this paper
• GLP-1’s role in neuroprotection: a systematic review

  2019cites this paper
• DA-JC1 improves learning and memory by antagonizing Aβ31–35-induced circadian rhythm disorder

  2019cites this paper
• MGCD0103, a selective histone deacetylase inhibitor, coameliorates oligomeric Aβ25‐35‐induced anxiety and cognitive deficits in a mouse model

  2018cites this paper
• Nucleoside reverse transcriptase inhibitors (NRTIs) induce proinflammatory cytokines in the CNS via Wnt5a signaling

  2017cites this paper
• Circadian clock-gastrointestinal peptide interaction in peripheral tissues and the brain.

  2017cites this paper
• Poly-N-methylated Aβ-Peptide C-Terminal fragments (MEPTIDES) reverse the deleterious effects of amyloid-β in rats

  2017cites this paper